+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
O

Actively Recruiting

Researchers are studying adults in Kazakhstan who have metabolic dysfunction-associated steatotic liver disease MASLD to better understand how this liver condition appears and is managed in everyday medical care. The study includes about 420 adults with MASLD, focusing on their health characteristics and how the disease affects them. A smaller group of about 65 participants in Almaty, who were already prescribed Ursosan by their doctors, will be followed to observe changes in liver-related health measures. The study has two parts a cross-sectional component where information from medical records, lab tests, liver imaging, and questionnaires is collected once for each participant and a prospective cohort component that follows the subgroup receiving Ursosan for approximately six months. During this follow-up, participants will have remote contacts at about 2 and 4 months and a final assessment at 6 months. Treatment decisions, including the use of Ursosan, are made by the participants doctors as part of routine care, not assigned by the study. Participants will provide data through routine medical care records, imaging scans, laboratory tests, and questionnaires about lifestyle and health. Researchers will measure liver health through imaging, liver enzyme levels, and fibrosis assessments. The study monitors changes in these measures over time, especially in the Ursosan subgroup. Participation may last up to six months for some, while others contribute data at a single time point, helping researchers understand MASLD and responses to Ursosan in real-world settings.

Age: 18Years - 65YearsAll Genders
7 locations
O

Actively Recruiting

Researchers are studying approximately 240 adult patients in Kazakhstan who have HER2-positive metastatic breast cancer mBC and are receiving anti-HER2 therapy, excluding trastuzumab deruxtecan. This observational retrospective study aims to evaluate real-world treatment approaches, clinical outcomes, and patient characteristics across 12 oncology centers to provide a representative sample of this population. The study covers patients diagnosed with mBC between January 2022 and December 2023 and includes a follow-up period to assess treatment impact. The study collects data retrospectively from patient medical records starting from the date of mBC diagnosis until either the patients death or the end of the study, which is at least 12 months after the latest diagnosis date. The treatments under review include all anti-HER2 therapies except trastuzumab deruxtecan. Researchers will analyze treatments received, diagnostic methods, therapy discontinuation reasons, lines of anticancer therapy, and efficacy in routine clinical practice. Participants data will be reviewed for at least 24 months following diagnosis, unless the patient died, moved, or refused therapy within that period. The primary outcome is to assess median progression-free survival and its rate over up to two years. Secondary outcomes include describing patient demographics, diagnostic and therapeutic patterns, treatment approaches, efficacy, reasons for stopping therapy, and number of therapy lines. This design involves no direct intervention, and data collection is based on existing medical records.

Age: 18Years - 99YearsAll Genders
12 locations
I

Actively Recruiting

Researchers are evaluating the real-world effects of adding anifrolumab to standard treatment for patients with Systemic Lupus Erythematosus SLE. This multi-country observational study aims to gather important information on how anifrolumab works in routine clinical practice across various countries, including those in the Gulf Cooperation Council, Latin America, Taiwan, and Egypt. The study uses standardized criteria and assessments to compare results across these locations. Participants who have been prescribed anifrolumab for the first time will be followed prospectively for one year after their initial infusion. The study also collects data from the year before starting anifrolumab to understand baseline health status. Clinical assessments relevant to SLE, including specific measures for skin symptoms, are used to monitor the patients. The study continues to collect data even if patients stop anifrolumab treatment, unless they withdraw consent. During the study, participants will undergo clinical and patient-reported evaluations at baseline and multiple points over one year, including assessments like PGA, SLEDAI-2K, CLASI, FACIT-Fatigue, LupusQoL, and EQ-5D-5L. Researchers will monitor these outcomes to understand how patients respond to anifrolumab in everyday care. The study period continues until the end of 2027 or until patients discontinue participation, with careful follow-up to capture ongoing health information.

Age: 18Years +All Genders
32 locations